How to Find and Sign a Compounding Pharmacy Partner as a Telehealth Startup

A telehealth startup signs a compounding pharmacy by getting a warm introduction through a provider group or an existing integration partner, arriving with its diligence packet already assembled, surviving the pharmacy's own vetting, negotiating a flat fair-market-value fee structure rather than anything tied to prescription volume or drug price, and refusing contract terms that trap patient and order data.

That is the mechanical answer. The rest is the procurement detail underneath it: who introduces you, what the pharmacy is quietly checking while you think you are the one doing diligence, which documents change hands, how long each stage takes, and which clauses decide whether you can leave. If you are still deciding which pharmacy to pursue, the selection criteria live in our diligence framework for choosing a compounding pharmacy. This post assumes a shortlist and a deal to get done.

Where do you actually find a compounding pharmacy that will take you?

The four channels that work are your medical director's existing pharmacy relationships, an introduction from a fulfillment or order-routing partner that is already integrated, accreditation and state board directories, and industry conferences. Cold outreach works worst by a wide margin, because a pharmacy's real constraint is compliance risk, not demand.

Start with your providers. A medical director who has been practising for a decade almost certainly has a pharmacy that already knows their name, and a pharmacy that trusts the prescriber moves faster on the entity behind them. Second best is an introduction through a platform already routing orders into that pharmacy, because the integration risk is retired.

With no warm path, work the directories rather than a contact form. The Accreditation Commission for Health Care publishes accredited PCAB facilities and every state board publishes its non-resident licensee list, which together build a target list already filtered for what would otherwise kill the deal at week six. Then get someone clinical on the first call; pharmacies open up faster when a licensed prescriber is in the room.

What does a compounding pharmacy diligence about you?

They are picking you too, and new operators consistently underestimate this. A compounding pharmacy carries the regulatory exposure of every client it fills for, so it screens your entity, prescribers, marketing claims, and volume forecast before it will quote you. Showing up prepared is the single largest lever on how fast onboarding moves. Expect them to look at the following, in roughly this order of seriousness:

• Prescriber licensure and state coverage. A roster of every prescribing provider with active state licenses, NPI numbers, and DEA registrations where controlled substances are in scope. Gaps stop the conversation, because the pharmacy cannot fill an order from a prescriber unlicensed in the patient's state.
• Marketing claims. They will read your landing pages, ad copy, and email flows. Compounding pharmacies draw FDA and state board attention for claims their clients make, so anything reading as a promise of efficacy, a comparison to an FDA-approved product, or a suggestion that a compounded drug is approved gets flagged before contracting.
• LegitScript and platform standing. If you intend to run paid acquisition, the pharmacy will want to know where you stand on LegitScript certification for telehealth, because ad status is a proxy for whether your business survives.
• Entity structure and insurance. Formation documents, EIN, W-9, certificate of good standing, ownership disclosure, and professional liability and errors and omissions certificates. Some also ask about corporate practice of medicine structure where a non-clinical entity sits above the provider group.
• Volume, category mix, and payment terms. A realistic forecast by category, not a hockey stick. Pharmacies plan capacity and raw material purchasing against it, and an inflated number costs you more credibility than a modest one.
• Privacy and clinical workflow. How intake works, where a licensed provider approves the order, how protected health information moves, and whether you can execute a business associate agreement.

The operators who move fastest assemble all of this into one packet before the first call. It compresses the timeline more than any negotiation tactic.

What does the onboarding sequence look like, stage by stage?

Onboarding runs in five stages: fit call, mutual diligence, paper, account and integration setup, then test orders and go-live. Durations vary enormously by pharmacy size, category, and how prepared you are, so treat the ranges below as the spread we observe from the fulfillment side, not a published benchmark.

Stage	What you provide	What the pharmacy provides	Typical duration
Fit call	Model overview, category list, state map, honest volume estimate	Formulary coverage, licensure footprint, integration options	Days
Mutual diligence	W-9 and entity docs, prescriber roster and licenses, insurance certs, marketing URLs	Accreditation certificates, dated state license list, SOP summaries, references	1 to 3 weeks
Paper	Redlines on the services agreement, BAA, and fee schedule	Draft agreement, BAA, pricing, formulary terms	1 to 4 weeks, the most variable stage
Account and integration setup	Endpoint config, webhook URL, your own order ID format	Portal account, API credentials, sandbox, product identifiers	Days to weeks
Test orders and go-live	Test orders, address checks, reconciliation	Test fills, status callbacks, cold-chain validation	1 to 2 weeks

Two honest caveats. Deals stall at the paper stage, and they stall on fees and exit terms rather than anything clinical. And integration is short only if the pharmacy exposes an inbound order API that accepts an identifier you generate. If the only path is manual entry into their portal, you have not saved time, you have deferred a much larger cost. See our walkthrough of LifeFile pharmacy integration for telehealth.

How should the fee structure be written?

This is the compliance-critical part of the deal. Flat, fair-market-value service fees set in advance are the defensible structure. Fees that scale with prescription volume, with the value of the drug dispensed, or with a spread you keep on the medication create federal Anti-Kickback Statute and, where laboratory services are involved, EKRA exposure. Get counsel before you sign a fee schedule.

Structure	How it works	Risk posture
Flat SaaS or service fee	Fixed monthly or per-seat fee, set in advance, unrelated to prescription count or drug price	Most defensible. Maps onto the personal services safe harbor requirements
Flat per-order technology fee	A fixed dollar amount per order processed, identical regardless of drug or cost	Common, but must be fair market value for services actually rendered. Counsel should paper it
Percentage of prescription revenue	Your fee is a share of what the patient pays for the medication	High risk. Compensation varies directly with the value of business generated
Spread pricing on the drug	You acquire at one price, bill the patient another, and keep the difference	High risk. Kickback questions plus state pharmacy ownership and fee-splitting issues
Per-prescription payment to a prescriber	A provider is paid per script written or patient steered	Prohibited territory. The core conduct both statutes target

What the statutes actually say

The federal Anti-Kickback Statute sits at 42 U.S.C. § 1320a-7b(b), inside a section titled "Criminal penalties for acts involving Federal health care programs." It makes it a felony to knowingly and willfully solicit, receive, offer, or pay remuneration, including any kickback, bribe, or rebate, in return for referring an individual for an item or service for which payment may be made under a federal health care program. The federal-program hook matters: subsection (f) reaches federally funded plans and state programs such as Medicaid.

EKRA, the Eliminating Kickbacks in Recovery Act at 18 U.S.C. § 220, closes the payor gap. It applies to any "health care benefit program," defined at 18 U.S.C. § 24(b) as any "public or private plan or contract, affecting commerce, under which any medical benefit, item, or service is provided to any individual." That reaches commercial payors and cash-pay arrangements in a way AKS does not. Penalties run to a fine of not more than $200,000, imprisonment of not more than 10 years, or both, for each occurrence.

One point that gets muddled constantly: EKRA's covered entities are recovery homes, clinical treatment facilities, and laboratories, with "laboratory" taking the broad CLIA definition. A compounding pharmacy that only dispenses is generally not one of the three. EKRA becomes directly relevant the moment your model routes lab work alongside prescriptions, which many hormone and metabolic programs do. Neither statute is the whole picture either, because many states have their own all-payor anti-kickback, fee-splitting, or patient-brokering statutes that apply regardless of who pays. A cash-pay telehealth business is not automatically outside the rules.

Why flat fees survive review

The AKS personal services and management contracts safe harbor at 42 C.F.R. § 1001.952(d) is the best available template even where it does not strictly apply, because it describes what a defensible commercial arrangement looks like: an agreement in writing and signed by the parties, covering all the services provided, with a term of not less than one year, and compensation set in advance, "consistent with fair market value in arm's-length transactions," and not determined in a manner that takes into account the volume or value of referrals or business otherwise generated.

Note what safe harbors are and are not. HHS OIG describes them as practices that, "although they potentially implicate the Federal anti-kickback statute, are not treated as offenses under the statute." Falling outside one does not make an arrangement illegal; it means the arrangement is judged on its facts rather than receiving automatic protection. That is why the written FMV structure matters, and why neolife prices as a flat SaaS subscription plus a flat per-order fee, never a percentage of prescription value.

Which contract terms decide whether you can ever leave?

Six clauses determine your exit: data portability, patient record access, exclusivity, notice and termination, formulary change rights, and minimums. Negotiate all six at signature, because none are renegotiable once volume is flowing and switching costs have accumulated.

• Data portability. Specify the export format, fields, and cadence in the contract. "We can provide a report on request" is not portability. You want machine-readable order, status, and shipment data, on demand, in a format your own system can ingest.
• Patient record access. Be precise here. The pharmacy has an independent legal obligation to retain its own dispensing records, which is a regulatory duty rather than a lock-in tactic. What you are negotiating is continued access to the records generated by your intake and your providers, plus confirmation that the pharmacy will not treat your patient list as its own.
• Exclusivity. Refuse it. Exclusivity converts every concentration risk below into an event you cannot mitigate. If a pharmacy insists, price the concession explicitly and cap it by category or by term.
• Notice and termination. A workable range is 30 to 90 days for convenience, with no automatic renewal that resets a long lock-in, plus a transition assistance obligation so in-flight orders and refills do not strand patients.
• Formulary change rights. The pharmacy needs the ability to discontinue or reformulate a product. You need advance written notice, because a formulation change is a patient communication event and a marketing rewrite on your side.
• Minimums and take-or-pay. Volume minimums are the quietest lock-in, because they punish you for adding a second pharmacy even when the contract technically permits one. If minimums exist, size them well below your forecast.

For a broader version of this exercise applied to any vendor in the stack, see our twelve questions to ask before signing a fulfillment platform.

Why is signing exactly one pharmacy a concentration risk?

Because a single pharmacy has at least five independent ways to interrupt your business, none of which you control: a licensure gap in a state you want to enter, a recall, a capacity crunch during a demand spike, a formulary discontinuation, or a regulatory action. Each is survivable. Each is fatal if you have nowhere to route.

None of this is a knock on any particular pharmacy; the strong ones are hard to replace on quality. The problem is structural. A single-threaded supply chain means growth into a new state waits on someone else's licensing timeline, and continuity during an interruption depends on a partner's spare capacity rather than your own architecture.

The mitigation is cheap if, and only if, your order layer can route to more than one filler. Signing a second pharmacy is a few weeks of the process above. It becomes expensive only when your operational source of truth lives inside the first pharmacy's portal, which turns adding a partner into a migration. The routing rules, licensure checks, and failover logic behind that are in multi-pharmacy routing, explained. Sign your first pharmacy well. Design so the second one is easy.

Talk to us

neolife is the fulfillment rail that sits on top of the compounding pharmacy you already use. A licensed provider approves every order, you keep your own storefront, and the order data stays yours as the system of record, which is what makes a second pharmacy a configuration change instead of a rip-and-replace. If you are negotiating a pharmacy agreement now and want the rail underneath it to be yours, talk to us.

This article is for informational purposes only and is not legal, medical, or regulatory advice; consult qualified counsel and licensed clinicians for your specific situation.